Oxford Cannabinoid Technologies Holdings PLC
LSE:OCTP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oxford Cannabinoid Technologies Holdings PLC
Cash Equivalents
Oxford Cannabinoid Technologies Holdings PLC
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Oxford Cannabinoid Technologies Holdings PLC
LSE:OCTP
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash Equivalents
£3.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cash Equivalents
$7.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
8%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash Equivalents
$217m
|
CAGR 3-Years
501%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
|
Allergy Therapeutics PLC
LSE:AGY
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Oxford Cannabinoid Technologies Holdings PLC
Glance View
Oxford Cannabinoid Technologies Holdings Plc is a pharmaceutical company that specializes in cannabinoid drug development with focus on the pain market. The Company’s wholly owned subsidiary is Oxford Cannabinoid Technologies Ltd (OCT). OCT is a pharmaceutical company, which is focused on developing cannabinoid-based prescription medicines. OCT’s drug development strategy includes the development of cannabinoid derivatives, natural phytocannabinoids (pCBs) and other drug compounds that interplay with the endocannabinoid system. OCT owns a library of approximately 93 cannabinoid derivatives and is focused on its lead drug candidate, OCT461201.
